Atopic Dermatitis in Atopy Predisposed Infants

NCT ID: NCT02906475

Last Updated: 2021-04-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to investigate the effectiveness of a standardized skin care regimen using a milk lotion once daily and a bathing addendum as needed during the first 52 weeks of life on the development of atopic Dermatitis (AD) compared to no structured skin care regimen in infants with atopic predisposition. Secondary objectives are to investigate the influence of a structured skin care regimen on the development of AD in the second year of life and the skin barrier function up to the infants' age of 2 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Atopic dermatitis is the most common cutaneous disease in childhood. First manifestations of AD usually appear early in life after the 3rd month of life and often precede other allergic diseases such as asthma or allergic rhinitis. AD affects over 15% of children up to school age in Germany and has a substantial impact on the lives and life quality of both the child and its family. Taking into account the burden on health-care resources, the impact on the quality of life of patients and their caregivers, together with increasing evidence that AD may progress to other allergic phenotypes, there is a clear need to improve disease prevention. Due to the childhood prevalence of the disease, prevention is focused on the postnatal period. It is recognized that prevention should start as soon as possible. Current studies suggest that epidermal barrier impairment is an important factor for the development of AD and other allergic diseases, with the gene encoding the filament-binding protein filaggrin (FLG) being the most widely replicated and most significant gene to influence atopic diseases. Currently, no standardized recommendations for preventive therapies exist for AD. Pilot studies have focused on interventions to enhance skin barrier function. Daily skin care with an emollient early after birth is considered to reduce the risk of atopic dermatitis in infants.

The study will be divided in 2 parts: The main study (Interventional period) lasts up to the child´s age of one year (52 weeks of life) and the follow-up period up to the second birthday.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention: standardized skin care regimen

Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.

Group Type OTHER

standardized skin care regimen

Intervention Type OTHER

Application of a standardized daily skin care regimen:

* milk lotion once daily and
* application of addendum for bathing as needed

Control

In the control group no predetermined or standardized skin care regimen is prescribed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standardized skin care regimen

Application of a standardized daily skin care regimen:

* milk lotion once daily and
* application of addendum for bathing as needed

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent (by both parents or legal representatives)
2. Healthy term newborns (gestational age: completed 37 weeks) born by mothers aged 18-45 years
3. Birth weight between 2.500 - 4.500 g
4. Age at enrolment 14 days
5. Infants at enhanced risk for developing AD (at least one parent or sibling with physician-diagnosed AD, asthma or allergic rhinitis/rhino conjunctivitis as reported by at least by one parent but in otherwise good overall health
6. Infant Nutrition: breastfeeding or cow's-milk based infant formula (including Hypoallergenic (HA) - based formula) feeding or combination
7. Phototype I, II, III or IV according to the Fitzpatrick classification.

Exclusion Criteria

1. Serious acquired or congenital diseases
2. Hydrops fetalis
3. Preterm children (\< completed 37th week of gestation)
4. Weight at birth \< 2500 g or \> 4500 g
5. Significant dermatitis at birth except seborrheic dermatitis on the scalp ("cradle cap")
6. Dermatological conditions influencing the study parameters, besides benign transient neonatal diseases
7. Any immunodeficiency disorder
8. Any severe genetic skin disorder
9. Any other serious condition that would make the use of skin care products inadvisable
10. Any other major medical problems that the investigator deems may increase the risk of adverse events with the intervention or in whom assessing the outcomes may be masked by the underlying problem or practically very difficult to assess
11. Participation in another clinical study
12. Reason to presume that the parents are unable to meet the study plan requirements
13. Nutrition: other than breastfeeding or cow's-milk based infant formula (e.g. soybased, goat-milk based formula etc.)
14. History of allergy or intolerance to investigational product's ingredient(s) of at least one subject's parent
15. Current topical or systemic drug treatment
16. Maternal antibiotic therapy in breastfed newborns
17. Infants of mothers supplementing probiotics during pregnancy and/or breastfeeding on a regular basis
Maximum Eligible Age

14 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role collaborator

HiPP GmbH & Co. Vertrieb KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ulrike Blume-Peytavi, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Charite Universitätsmedizin Berlin

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charite Universitätsmedizin Berlin

Berlin, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Simpson EL, Keck LE, Chalmers JR, Williams HC. How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol. 2012 Jul;130(1):137-44. doi: 10.1016/j.jaci.2012.01.075. Epub 2012 Mar 15.

Reference Type BACKGROUND
PMID: 22424882 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

508276

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Moisturizer to Prevent Atopic Dermatitis
NCT03808532 WITHDRAWN PHASE2